Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 12, 2012

NovAliX to Use Graffinity Screening Platform in Drug Discovery Deal with Teijin Pharma

  • NovAliX will use its Graffinity SPR-based screening platform in a drug discovery program of Teijin Pharma. NovAliX will use the technology to identify novel chemotypes, and then apply its native nano-MS technology to further characterize selected small molecule hit structures.

    Under the multitarget drug discovery collaboration, French-owned NovAliX said it will receive technology access fees as well as further research funding payments from the collaboration, its first with Teijin but its second with a Japanese pharmaceutical company.

    NovAliX-owned Graffinity Pharmaceuticals announced in March 2011 that it would apply the fragment based screening platform to a drug discovery program of Shionogi & Co., in return for unspecified technology access fees and payments.



Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »